For your patients
Hospital-based preoperative clinic applies ERAS and Strong for Surgery guidelines to optimize patients for surgery(0)
The results of an ERAS initiative and a Strong for Surgery checklist applied to colorectal surgery patients at CHRISTUS St. Michael Health System, Texarkana, TX, are summarized.
A summary of the ACS Clinical Research Program sessions at Clinical Congress 2019 is provided.
The potential role of NCDB data in treating rare malignancy is explored.
The results of a quality improvement initiative to reduce length of stay for arthroplasty patients at the Kaiser Westside Medical Center (KWMC), Hillsboro, OR, are summarized.
Modified FOLFIRINOX is superior to gemcitabine as adjuvant therapy for resected pancreatic cancer: The PRODIGE 24/CCTG PA6 Trial
The study design and findings of the PRODIGE 24/CCTG PA6 Trial are outlined, which showed improved survival with modified FOLFIRINOX for resected pancreatic cancer patients.
More in this category
- ERAS program improves outcomes in patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy
- ALCHEMIST trial has potential to improve outcomes after lung cancer resection
- Comparison of NCDB and CBTRUS demographic data for astrocytoma and glioblastoma
- New protocol leads to improved trauma decannulation rate
- Could axillary reverse mapping be useful in reducing surgical comorbidities?
- Trauma at Thanksgiving
- Routine Foley catheter placement affects postoperative UTIs in bariatric surgery patients
- Evolution in the management of desmoid tumors: Challenging the role of upfront surgical resection
- Bloodshot: Ocular lacerations from gunshot wounds
- Enhanced recovery program benefits frail colon and rectal surgery patients
- Putting the needle before the knife: Minimally invasive approaches to diagnostic lymph node biopsy in melanoma
- Tawny trauma: Cirrhosis affects patient response to trauma
- Gastric cancer: Recent updates in surgical and multimodality therapy
- Under the influence: Alcohol-related trauma
- Organ preservation in rectal adenocarcinoma: The OPRA Trial